Benitec Biopharma, a small US biotech company, said on October 28, 2026 that every patient treated so far with its experimental gene therapy for a rare inherited swallowing disorder met its definition of a responder.1 The therapy, called BB-301, is being tested in people with oculopharyngeal muscular dystrophy (OPMD), a disease that slowly weakens the muscles of the eyelids and throat.1
The figures come from an early study with nine people and no comparison group. They are company-reported interim results, meaning a snapshot taken while the study is still running, and they have not been published in a peer-reviewed journal.
What happened
The study has two dose groups so far: six people who got a lower dose and three who got a higher dose.1 All six lower-dose patients have now been followed for 12 months. Among the higher-dose patients, one has been followed for nine months and two for three months.1
The company compared the two groups three months after treatment on several measures:1
- Clearing the throat after a swallow: 67% of lower-dose patients responded, compared with 100% of higher-dose patients.
- A timed water-drinking test: 17% of lower-dose patients responded, compared with 67% of higher-dose patients.
- A swallowing questionnaire (the Sydney Swallow Questionnaire, where patients rate their own symptoms): 100% in both groups.
- How tightly the throat muscles close: 67% in both groups.
Overall, Benitec said all nine patients qualified as formal responders, and that the lower-dose group showed lasting improvements in swallowing.1 The company also said no serious adverse events, meaning serious side effects, have occurred in anyone treated with BB-301 to date.1 In May 2026, the company had described two patients treated at the higher dose; the new update reports on three.21
The disease and the therapy
OPMD is usually caused by a small repeated section in a gene called PABPN1, and it typically appears in mid-adulthood.1 It is mostly inherited in a dominant pattern, meaning one copy of the faulty gene from one parent is enough to cause it.1 In a 2021 statement, Benitec said the disease affects about 15,000 people in the United States, Canada, Western Europe and Israel.3 The company said patients lose the ability to swallow liquids and solids, which can lead to long-term malnutrition, food or drink going into the lungs, and deadly lung infections called aspiration pneumonia.3 At that time, Benitec said no medicines were approved for OPMD and no surgery could change its long-term course.3
BB-301 uses a harmless, modified virus called AAV9 as a delivery vehicle.4 It is designed to do two jobs at once: carry a healthy copy of the PABPN1 gene into muscle cells, and use a method called RNA interference to destroy the messages made by the faulty gene.4 This is sometimes described as “silence and replace.”4
The treatment is a one-time procedure. Surgeons inject it into two throat muscles, the middle and inferior pharyngeal constrictors, during open surgery under general anesthesia.45
The evidence so far
The study is listed on the US trial registry as a Phase 1b/2a trial, an early-stage test of safety and the best dose, that started in November 2023.5 It is open-label, meaning patients and doctors know who is getting the treatment, and it plans to enroll about 30 people.5 To join, patients must first spend at least six months in a separate Benitec study that tracks how the disease progresses without treatment.5 Those earlier measurements serve as each person’s own starting point.
The registry lists safety and measures of how much food and liquid is left in the throat after swallowing among the main goals.5 These are measured with X-ray videos of swallowing.6 The trial is designed to test up to three doses in up to 18 people, and then the chosen dose in up to 12 more.4
Results have built up over several updates. In 2024, NeurologyLive reported data on the first patient: six months after a low dose, the amount of residue left in the throat after swallowing thin liquid had fallen to an average of 2.8%, from 4.9% during the earlier tracking period.6 That patient’s questionnaire score also improved, from an average of 1136 before treatment to 820 after six months (lower is better).6 Earlier company updates listed by Stock Titan say all six lower-dose patients met the company’s response criteria and that the first patient still showed improvements at 24 months.1 A late-breaking abstract at the Muscular Dystrophy Association conference in March 2026 described lasting responses at the lower dose and a deeper response at the higher dose after three months.2
What it does not show yet
A “100% response rate” sounds strong, but it rests on nine people. The higher-dose comparison covers only three patients, and the direct comparison between doses is limited to three months, a point Stock Titan’s own summary flags.1 Two of the three higher-dose patients have only three months of follow-up.1
The sources do not spell out exactly how Benitec defines a “formal responder.” Response rates also varied a lot by measure: only one of six lower-dose patients responded on the timed water-drinking test at three months.1
Because there is no group given a dummy treatment, the study cannot separate the therapy’s effect from other things, such as patients’ expectations on the self-rated questionnaire. Side effects also need longer study. Muscular Dystrophy News noted that the side-effect profile is still largely unknown, and that one early patient had moderate acid reflux that went away with time.4
Who is behind it
Benitec, listed on the Nasdaq stock exchange, sponsors the trial and is the source of all the efficacy figures.15 Its chief executive and executive chairman is Jerel A. Banks.6 In 2024 he said:
“Facilitating reductions in the quantities of solid food and liquid that remain in the throat post-swallow is believed to be a central indicator of improvement of swallowing and the reduction of the risk of aspiration in subjects suffering from OPMD.”
That quote appeared in NeurologyLive’s coverage.6 As of March 31, 2026, the company reported about $184.8 million in cash and a quarterly net loss of $11.9 million.2
The US Food and Drug Administration has given BB-301 orphan drug designation, a status for treatments of rare diseases.6 Earlier company updates also mention Fast Track designation, which can speed up the review process.1 Before human testing, Benitec tested the therapy in mice and beagle dogs.3
What to watch next
Benitec says it is moving toward a pivotal study, the larger trial meant to support an approval request, in mid-2027.1 Earlier in 2026, the company said it planned to talk with the FDA to settle the design of that study.2 The registry lists the current trial’s main completion date as November 2030.5
For now, the therapy is available only inside Benitec’s trials. The company says it is not accepting requests for compassionate use, meaning access outside a trial.7 Key things to watch: longer follow-up for the three higher-dose patients, whether the results appear in a peer-reviewed journal, and how the pivotal study measures benefit against a comparison group.
